vs
Apellis Pharmaceuticals, Inc.（APLS）与RENASANT CORP（RNST）财务数据对比。点击上方公司名可切换其他公司
RENASANT CORP的季度营收约是Apellis Pharmaceuticals, Inc.的1.4倍（$273.8M vs $199.9M），RENASANT CORP净利率更高（32.2% vs -29.5%，领先61.7%），过去两年RENASANT CORP的营收复合增速更高（29.3% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
瑞耐桑特银行是美国密西西比州图珀洛的区域商业金融机构，母公司为瑞耐桑特公司，在阿拉巴马、佛罗里达、佐治亚、密西西比、路易斯安那、田纳西、北卡罗来纳、南卡罗来纳八州拥有280多家分支机构，旗下还运营内容平台“瑞耐桑特国度”，发布博客及节目内容。
APLS vs RNST — 直观对比
营收规模更大
RNST
是对方的1.4倍
$199.9M
净利率更高
RNST
高出61.7%
-29.5%
两年增速更快
RNST
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $273.8M |
| 净利润 | $-59.0M | $88.2M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 32.2% |
| 营收同比 | -5.9% | — |
| 净利润同比 | -62.2% | 112.5% |
| 每股收益（稀释后） | $-0.40 | $0.94 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSRNST
| Q1 26 | — | $273.8M | ||
| Q4 25 | $199.9M | $278.4M | ||
| Q3 25 | $458.6M | $269.5M | ||
| Q2 25 | $178.5M | $267.2M | ||
| Q1 25 | $166.8M | $170.7M | ||
| Q4 24 | $212.5M | $167.1M | ||
| Q3 24 | $196.8M | $220.3M | ||
| Q2 24 | $199.7M | $163.8M |
净利润APLSRNST
| Q1 26 | — | $88.2M | ||
| Q4 25 | $-59.0M | $78.9M | ||
| Q3 25 | $215.7M | $59.8M | ||
| Q2 25 | $-42.2M | $1.0M | ||
| Q1 25 | $-92.2M | $41.5M | ||
| Q4 24 | $-36.4M | $44.7M | ||
| Q3 24 | $-57.4M | $72.5M | ||
| Q2 24 | $-37.7M | $38.8M |
营业利润率APLSRNST
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 34.8% | ||
| Q3 25 | 48.7% | 27.9% | ||
| Q2 25 | -18.6% | 1.0% | ||
| Q1 25 | -50.0% | 30.4% | ||
| Q4 24 | -12.3% | 29.8% | ||
| Q3 24 | -24.0% | 44.2% | ||
| Q2 24 | -14.7% | 29.6% |
净利率APLSRNST
| Q1 26 | — | 32.2% | ||
| Q4 25 | -29.5% | 28.4% | ||
| Q3 25 | 47.0% | 22.2% | ||
| Q2 25 | -23.6% | 0.4% | ||
| Q1 25 | -55.3% | 24.3% | ||
| Q4 24 | -17.1% | 26.8% | ||
| Q3 24 | -29.2% | 32.9% | ||
| Q2 24 | -18.9% | 23.7% |
每股收益（稀释后）APLSRNST
| Q1 26 | — | $0.94 | ||
| Q4 25 | $-0.40 | $0.78 | ||
| Q3 25 | $1.67 | $0.63 | ||
| Q2 25 | $-0.33 | $0.01 | ||
| Q1 25 | $-0.74 | $0.65 | ||
| Q4 24 | $-0.30 | $0.70 | ||
| Q3 24 | $-0.46 | $1.18 | ||
| Q2 24 | $-0.30 | $0.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $1.2B |
| 总债务越低越好 | — | $806.2M |
| 股东权益账面价值 | $370.1M | $3.9B |
| 总资产 | $1.1B | $27.1B |
| 负债/权益比越低杠杆越低 | — | 0.21× |
8季度趋势，按日历期对齐
现金及短期投资APLSRNST
| Q1 26 | — | $1.2B | ||
| Q4 25 | $466.2M | $1.1B | ||
| Q3 25 | $479.2M | $1.1B | ||
| Q2 25 | $370.0M | $1.4B | ||
| Q1 25 | $358.4M | $1.1B | ||
| Q4 24 | $411.3M | $1.1B | ||
| Q3 24 | $396.9M | $1.3B | ||
| Q2 24 | $360.1M | $851.9M |
总债务APLSRNST
| Q1 26 | — | $806.2M | ||
| Q4 25 | — | $499.8M | ||
| Q3 25 | — | $558.9M | ||
| Q2 25 | — | $557.0M | ||
| Q1 25 | — | $433.3M | ||
| Q4 24 | — | $430.6M | ||
| Q3 24 | — | $433.2M | ||
| Q2 24 | — | $428.7M |
股东权益APLSRNST
| Q1 26 | — | $3.9B | ||
| Q4 25 | $370.1M | $3.9B | ||
| Q3 25 | $401.2M | $3.8B | ||
| Q2 25 | $156.3M | $3.8B | ||
| Q1 25 | $164.2M | $2.7B | ||
| Q4 24 | $228.5M | $2.7B | ||
| Q3 24 | $237.1M | $2.7B | ||
| Q2 24 | $264.3M | $2.4B |
总资产APLSRNST
| Q1 26 | — | $27.1B | ||
| Q4 25 | $1.1B | $26.8B | ||
| Q3 25 | $1.1B | $26.7B | ||
| Q2 25 | $821.4M | $26.6B | ||
| Q1 25 | $807.3M | $18.3B | ||
| Q4 24 | $885.1M | $18.0B | ||
| Q3 24 | $901.9M | $18.0B | ||
| Q2 24 | $904.5M | $17.5B |
负债/权益比APLSRNST
| Q1 26 | — | 0.21× | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.16× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.18× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSRNST
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $271.5M | ||
| Q3 25 | $108.5M | $135.5M | ||
| Q2 25 | $4.4M | $-77.3M | ||
| Q1 25 | $-53.4M | $106.2M | ||
| Q4 24 | $19.4M | $106.4M | ||
| Q3 24 | $34.1M | $-1.7M | ||
| Q2 24 | $-8.3M | $-49.1M |
自由现金流APLSRNST
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $237.8M | ||
| Q3 25 | $108.3M | $120.1M | ||
| Q2 25 | $4.4M | $-87.5M | ||
| Q1 25 | $-53.4M | $101.3M | ||
| Q4 24 | $19.3M | $92.8M | ||
| Q3 24 | — | $-5.3M | ||
| Q2 24 | $-8.4M | $-52.6M |
自由现金流率APLSRNST
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 85.4% | ||
| Q3 25 | 23.6% | 44.6% | ||
| Q2 25 | 2.5% | -32.7% | ||
| Q1 25 | -32.0% | 59.4% | ||
| Q4 24 | 9.1% | 55.5% | ||
| Q3 24 | — | -2.4% | ||
| Q2 24 | -4.2% | -32.1% |
资本支出强度APLSRNST
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 12.1% | ||
| Q3 25 | 0.0% | 5.7% | ||
| Q2 25 | 0.0% | 3.8% | ||
| Q1 25 | 0.0% | 2.8% | ||
| Q4 24 | 0.0% | 8.2% | ||
| Q3 24 | 0.0% | 1.6% | ||
| Q2 24 | 0.0% | 2.1% |
现金转化率APLSRNST
| Q1 26 | — | — | ||
| Q4 25 | — | 3.44× | ||
| Q3 25 | 0.50× | 2.27× | ||
| Q2 25 | — | -75.92× | ||
| Q1 25 | — | 2.56× | ||
| Q4 24 | — | 2.38× | ||
| Q3 24 | — | -0.02× | ||
| Q2 24 | — | -1.26× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
RNST
| Net Interest Income | $223.6M | 82% |
| Noninterest Income | $50.3M | 18% |
